Wasdell to open new 'futureproof' facility in Ireland
New facility to carry out EU release testing ensuring continuous supply for customers regardless of the outcome of Brexit negotiations.
The Wasdell Group is opening a new facility in Dundalk, Ireland in Spring 2019 following a €30 million investment.
The 90,000 sq. ft facility will allow Wasdell to offer quality control (QC) import testing for pharmaceutical products, as well as a variety of current and novel packaging technologies. It will also boost its storage and distribution services outside of the UK.
The facility will also futureproof the company’s operations in the event of a hard Brexit when the UK exits the European Union (EU) in March 2019. By giving Wasdell a foothold in Ireland, it will be able to carry out EU release testing ensuring continuous supply for customers regardless of the outcome of Brexit negotiations.
Martin Tedham, CEO at The Wasdell Group said: “With our new facility, we are not only increasing our packaging and analytical testing capacity to better service new and future customers, but with Brexit on the horizon, we are ensuring challenges and costs are minimised by preparing for every eventuality.
”This investment will provide our customers with a robust contingency plan, protecting critical supply chains and ensuring continuous supply of pharmaceutical products post-March 2019.
Almost 75% of our current turnover is export business and as our customer base is continuing to grow significantly in the US, this facility will allow Wasdell to remain a secure stepping stone into the European market.
”In addition, the company has experienced growth in the Irish market over the past four years making the country a logical choice for our latest expansion.”
The Dundalk facility is the latest phase in Wasdell’s investment plan to increase capability and capacity and follows the announcement of its new £500K microbiological and analytical laboratory at its Newcastle, UK, site. The company’s ongoing expansion plan will benefit over 120 of its current customers.
Martin Tedham continued: ”The facility also demonstrates our investment into the future of Wasdell, strengthening and preparing the company for forecasted growth. And, as a growing pharmaceutical hub, Ireland also offers an abundance of local talent from a recruitment perspective with strong universities that will be right on our doorstep.”
Building work on the site, which is expected to fully operational by spring 2019, began in August 2018. The new facility is expected to create around 800 jobs ranging from senior management to roles across operations, quality, technical, commercial, financial, warehousing, laboratory and production.
The Wasdell Group is also planning to build an additional facility close to the Dundalk site to expand its distribution offering.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance